Latest period
$1.30B
YoY change
+25.1%
5Y CAGR
+20.2%
Peak year (2025)
$1.52B
Latest annual
$1.52B
Total Equity history chart for Insulet (PODD) from 2002 to 2025
Latest: $1.52B
Total Equity growth chart for Insulet (PODD) from 2002 to 2025
Latest: +25.1%
Total Equity history table for Insulet (PODD) from 2002 to 2025
| 2025 | $1.52B | +25.1% | +$303.60M | ||
| 2024 | $1.21B | +65.4% | +$478.90M | ||
| 2023 | $732.70M | +53.8% | +$256.30M | ||
| 2022 | $476.40M | -14.4% | −$79.90M | ||
| 2021 | $556.30M | -7.8% | −$47.30M | ||
| 2020 | $603.60M | +695.3% | +$527.70M | ||
| 2019 | $75.90M | -64.2% | −$136.20M | ||
| 2018 | $212.10M | +33.8% | +$53.58M | ||
| 2017 | $158.52M | +151.0% | +$95.37M | ||
| 2016 | $63.15M | +85.5% | +$29.10M | ||
| 2015 | $34.05M | -59.4% | −$49.78M | ||
| 2014 | $83.83M | -32.7% | −$40.77M | ||
| 2013 | $124.60M | +182.0% | +$80.42M | ||
| 2012 | $44.18M | -38.1% | −$27.22M | ||
| 2011 | $71.40M | +7.8% | +$5.17M | ||
| 2010 | $66.23M | +25.3% | +$13.37M | ||
| 2009 | $52.86M | +1136.7% | +$48.58M | ||
| 2008 | $4.27M | -95.4% | −$88.00M | ||
| 2007 | $92.28M | -190.7% | +$194.04M | ||
| 2006 | −$101.77M | +54.0% | −$35.67M | ||
| 2005 | −$66.09M | +48.5% | −$21.58M | ||
| 2004 | −$44.51M | +45.2% | −$13.86M | ||
| 2003 | −$30.65M | +64.3% | −$12.00M | ||
| 2002 | −$18.65M | — | — |
- 2025$1.52B+25.1%
- 2024$1.21B+65.4%
- 2023$732.70M+53.8%
- 2022$476.40M-14.4%
- 2021$556.30M-7.8%
- 2020$603.60M+695.3%
- 2019$75.90M-64.2%
- 2018$212.10M+33.8%
- 2017$158.52M+151.0%
- 2016$63.15M+85.5%
- 2015$34.05M-59.4%
- 2014$83.83M-32.7%
- 2013$124.60M+182.0%
- 2012$44.18M-38.1%
- 2011$71.40M+7.8%
- 2010$66.23M+25.3%
- 2009$52.86M+1136.7%
- 2008$4.27M-95.4%
- 2007$92.28M-190.7%
- 2006−$101.77M+54.0%
- 2005−$66.09M+48.5%
- 2004−$44.51M+45.2%
- 2003−$30.65M+64.3%
- 2002−$18.65M—
Total Equity values are taken from Insulet's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Equity at Insulet (PODD)
According to Insulet's latest reported financial statements, the company's latest reported total equity is $1.30B. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Insulet (PODD) total equity is $1.52B – grew 25.1% year-over-year.
Insulet total equity compound annual growth for the 2020–2025 (5 years) window is +20.2%, sustaining 3 straight years of year-over-year growth.
$1.52B stands as the all-time-high annual total equity, posted in 2025, against a low of −$101.77M during 2006.
Insulet Total Equity by Year
Insulet Total Equity 2025: $1.52B
2025's total equity for Insulet came in at $1.52B, grew 25.1% from 2024. This figure represents the highest annual value in the available history.
Insulet Total Equity 2024: $1.21B
Insulet posted total equity of $1.21B in 2024, surged 65.4% from 2023.
Insulet Total Equity 2023: $732.70M
In 2023, Insulet reported total equity of $732.70M, surged 53.8% from 2022.
Insulet Total Equity 2022: $476.40M
Insulet total equity in 2022 was $476.40M, declined 14.4% below 2021.
Insulet Total Equity 2021: $556.30M
Insulet total equity in 2021 was $556.30M.
See more financial history for Insulet (PODD).
Sector peers by Total Equity
Healthcare peers of Insulet (PODD), ranked by their latest total equity
| $94.11B | |
| $81.54B | |
| $52.61B | |
| $48.67B | |
| $30.52B | |
| $26.54B | |
| $8.66B | |
| −$3.27B |
- $94.11B
- $81.54B
- $52.61B
- $48.67B
- $30.52B
- $26.54B
- $8.66B
- −$3.27B
Frequently asked questions
Insulet (PODD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation